GREY:DGCRF - Post by User
Post by
Konderoon Jan 25, 2014 10:49am
303 Views
Post# 22133640
It's not over...
It's not over...
The subsidy granted by NRC shows the confidence the scientific community put in Cur's know-how. It might also give the company a powerful bargaining power beside big pharmas that are willing to conquer the market of prostate cancer. The addition of more biomarkers to the PCA3 test in order to improve its specificity and sensibility might give an insurmountable lead in front of competitors. ( by the way, if CUR buy something to HOLX, an eventual new partner would be part of the deal. That's Bilodeau's job to find out that partner. )
About the GCC test, Cur's strategy, by looking for several partners, seems to be the reduction of risk and the creation of dynamism by emulation.
A great deal of work for Bilodeau !
Fantomatus